178 related articles for article (PubMed ID: 31610901)
1. Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?
de Joode K; van der Veldt AAM
Eur Urol; 2020 Mar; 77(3):e76-e77. PubMed ID: 31610901
[No Abstract] [Full Text] [Related]
2. Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3-5.
Tang Y; Hu X; Wu K; Shao Y; Li X
Eur Urol; 2023 Mar; 83(3):e73. PubMed ID: 36526493
[No Abstract] [Full Text] [Related]
3. Reply to Yongbao Wei, Ruochen Zhang, and Le Lin's Letter to the Editor re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. 2022;82:e88.
Ljungberg B; Bedke J; Capitanio U; Bex A
Eur Urol; 2022 Oct; 82(4):e111-e112. PubMed ID: 35773149
[No Abstract] [Full Text] [Related]
4. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
5. Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5.
Capitanio U; Bedke J; Albiges L; Volpe A; Giles RH; Hora M; Marconi L; Klatte T; Abu-Ghanem Y; Dabestani S; Fernández Pello S; Hofmann F; Kuusk T; Campi R; Tahbaz R; Powles T; Ljungberg B; Bex A
Eur Urol; 2023 Mar; 83(3):e74-e75. PubMed ID: 36526491
[No Abstract] [Full Text] [Related]
6. Re: Nizar M. Tannir, Eric Jonasch, Laurence Albiges, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN):A Randomized Multicenter Phase 2 Trial. Eur Urol 2016;69:866-74.
Yang Z; Qi L; Chen M
Eur Urol; 2017 Jan; 71(1):e23-e24. PubMed ID: 27344295
[No Abstract] [Full Text] [Related]
7. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
[No Abstract] [Full Text] [Related]
8. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
Santoni M; Montironi R; Battelli N; Massari F
Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
[No Abstract] [Full Text] [Related]
9. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
[TBL] [Abstract][Full Text] [Related]
10. Re: Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al. Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.003.
Wang Z; Zhao Y; Zhang Y
Eur Urol; 2022 May; 81(5):e120. PubMed ID: 35232603
[No Abstract] [Full Text] [Related]
11. Re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019:76:136-7.
Marconi L; Bensalah K; Bex A;
Eur Urol; 2019 Jul; 76(1):e12-e13. PubMed ID: 30922689
[No Abstract] [Full Text] [Related]
12. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
Singla N; Margulis V
Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
[No Abstract] [Full Text] [Related]
13. Reply to Lorenzo Marconi, Karim Bensalah, and Axel Bex's Letter to the Editor re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019;76:136-7.
Verhagen PCMS; Boevé ER
Eur Urol; 2019 Jul; 76(1):e14. PubMed ID: 30910344
[No Abstract] [Full Text] [Related]
14. Re: Bimal Bhindi, Christine M. Lohse, Phillip J. Schulte, et al. Predicting Functional Outcomes After Partial and Radical Nephrectomy. Eur Urol 2019;75:766-72: Partial Nephrectomy: "Geocentrism" of the 21st century in the Church of Urology?
Takahashi T
Eur Urol; 2019 Sep; 76(3):e65-e66. PubMed ID: 31164251
[No Abstract] [Full Text] [Related]
15. Re: Maurice et al: Nonclinical Factors Predict Selection of Initial Observation for Renal Cell Carcinoma (Urology 2015;86:892-900).
Morlacco A; Karnes RJ
Urology; 2016 Feb; 88():229. PubMed ID: 26680243
[No Abstract] [Full Text] [Related]
16. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
[No Abstract] [Full Text] [Related]
17. Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. Eur Urol 2021;80:442-9. Eur Urol 2021;80:e100: Reply from the European Association of Urology Equity, Diversity, and Inclusion Task Force.
Carmen Mir M; Greenwell T; O'Kelly F; Proietti S; Laukhtina E; Mertens L; Morgenstern S; Ouzaid I;
Eur Urol; 2022 Jan; 81(1):e26-e27. PubMed ID: 34772550
[No Abstract] [Full Text] [Related]
18. Re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol. 2021;80:760-2: Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki.
Takahashi T
Eur Urol; 2022 Feb; 81(2):e44-e45. PubMed ID: 34887116
[No Abstract] [Full Text] [Related]
19. Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Zhao B; Xing H; Ma W
Eur Urol; 2023 Jul; 84(1):e16-e17. PubMed ID: 37061446
[No Abstract] [Full Text] [Related]
20. Reply to Binghao Zhao, Hao Xing, and Wenbin Ma's Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109-116.
Ernst MS; Heng DYC
Eur Urol; 2023 Jul; 84(1):e18-e19. PubMed ID: 37080894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
